Back to top
Clinical stage:
Human POC trial

Currently undergoing initial proof of concept human trials

N4 Pharma is seeking to improve the speed at which Sildenafil (commonly known as Viagra) takes effect whilst also extending its duration of action. It filed a UK patent in April 2016 and PCT patent in March 2017 to protect its reformulation methodology and unique ability for faster onset and longer duration.

The erectile dysfunction market had global annual sales of approximately $4.6 billion* in 2016 and is expected to drop to $3.2 billion by 2022 due to the expected patent expiry of Viagra and Cialis.

*Source: Evaluate Pharma